Representing Animals Foundation
6.6.2024 13:35:39 CEST | ACCESS Newswire | Press release
WINCHESTER, UK / ACCESSWIRE / April 23, 2024 / The longest, most comprehensive peer-reviewed study so far has demonstrated that dogs fed nutritionally-sound vegan diets maintain health outcomes as well as dogs fed meat. The study, published in leading scientific journal PLOS ONE, comprehensively assessed the health of 15 dogs by analysing blood cells and biochemistry, blood nutrient levels, urine, veterinary clinical parameters, and monthly pet owner questionnaires. The dogs were fed solely vegan diets based on pea protein for an entire year - just under one tenth of an average dog lifespan, or around seven human years.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.Overweight or obese dogs lost weight, whilst the remainder maintained normal weight. No clinically significant changes occurred within blood and urine. Blood levels of amino acids and vitamins were all generally maintained.
In a few cases, previous deficiencies following a meat-based diet either improved or disappeared, including L-taurine and L-carnitine (important for cardiac health), vitamin D (indispensable for immunity and bone health), and folate (required to produce red blood cells).
The study was particularly interesting, given recent suggestions that peas might contribute to heart disease in dogs in the US. Although no credible evidence has been found, such concerns have persisted in some quarters. In the current study, dogs were fed pea-based vegan pet food, for one year. Blood markers of cardiac health were assessed, with no signs of heart disease found. Indeed, in some cases indicators of cardiac health improved.
Stated lead researcher, veterinarian Dr. Annika Linde from the Western University of Health Sciences near Los Angeles says, "Evolutionary adaptations have resulted in a digestive system that enables dogs to maintain health on nutritionally complete omnivorous diets, including those free of animal ingredients. Our study offers new evidence on outcomes in clinically healthy dogs who thrive without consumption of animal-derived ingredients. Notably, foods produced independent of factory farming are also more sustainable and ethical."
Study co-author Dr. Melgarejo highlighted the potential environmental benefits of such diets, "If dogs and cats in the U.S. were their own nation, they would rank fifth in global meat consumption, surpassed only by Russia, Brazil, USA, and China, according to the UCLA Institute of the Environment and Sustainability."
Veterinary Professor Andrew Knight has published several of the key studies in this field, including very large-scale studies showing that both dogs and cats normally achieve equivalent or superior health outcomes, when fed nutritionally-sound vegan diets. He also analysed the environmental benefits of vegan pet diets in a major recent study. He stated that "If all the world's dogs went vegan, it would save more greenhouse gases than those emitted by the UK, land larger than Mexico, and 450 million additional people could be fed with food energy savings - more than the entire EU population. With 13 studies now demonstrating good health outcomes achieved by nutritionally-sound vegan pet diets, and several others demonstrating major environmental benefits, a compelling case now exists for environmentally-friendly vegan pet diets."
Contact Information:
Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@winchester.ac.uk
SOURCE: Representing Animals Foundation
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
